Novo Nordisk Secures Key EU Approval for Higher-Dose Weight-Loss Drug
Published on 02/19/2026 at 13:58 | Redaktion boerse-global.de
Novo Nordisk has received crucial regulatory backing from Brussels, providing a positive counterpoint to recent stock market declines and heightened competitive pressures. The European Commission has approved a high-dose formulation of the blockbuster weight-loss medication Wegovy, a strategic move analysts view as essential for the pharmaceutical giant to defend its market leadership against rivals such as Eli Lilly.
This authorization arrives at a pivotal moment for the company. Novo Nordisk’s shares have faced significant pressure, shedding approximately 48 percent of their value over a twelve-month period. This downturn was partly fueled by disappointing 2026 forecasts, which project a currency-adjusted sales decline of up to 13 percent. The EU’s green light for Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
